Journal for immunotherapy of cancer · 2026
AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.
СтатьяКлиническое исследование I фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lu Shun, Yu Yan, Zhang Jun, Wang Qiming, Cho Eun Kyung, Zhao Jun, Kim Se Hyun, Lee Youngjoo, Clay Timothy D, Yang Tsung-Ying, Chang Gee-Chen, Yang Haiyuan, Zuo Yunxia, Liu Rui, Sun Pu, Kim Hye Ryun
Аннотация
BACKGROUND: Patients with metastatic non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (ES-SCLC) have poor prognosis and survival with current standard of care. Several checkpoint inhibitor combinations have been evaluated clinically. We report outcomes from the dose-expansion cohorts of patients with NSCLC or ES-SCLC from the AdvanTIG-105 clinical trial.
METHODS: AdvanTIG-105 was a phase I/Ib, open-label, multicenter clinical trial of ociperlimab plus tislelizumab with or without chemotherapy in patients with unresectable locally advanced or metastatic solid tumors, including NSCLC and ES-SCLC (NCT04047862). The dose-expansion cohorts received ociperlimab (anti-T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domain) 900 mg intravenously and tislelizumab (anti-programmed cell death-protein 1) 200 mg intravenously every 3 weeks (Q3W) ± chemotherapy for four cycles, followed by ociperlimab 900 mg intravenously and tislelizumab 200 mg intravenously Q3W. The primary endpoint was the objective response rate. Other key endpoints included duration of response and safety.
RESULTS: As of August 7, 2024, patients with untreated squamous NSCLC (sqNSCLC; n=41), untreated non-sqNSCLC (n=43), untreated programmed cell death-ligand 1+ NSCLC (tumor cell ≥1%; n=45), checkpoint inhibitor-experienced NSCLC (n=26), and untreated ES-SCLC (n=43) were treated in the dose-expansion phase; of these, 40, 42, 45, 26, and 41 patients, respectively, were efficacy evaluable. ORR (95% CI) was 55.0% (38.5% to 70.7%), 54.8% (38.7% to 70.2%), 40.0% (25.7% to 55.7%), 7.7% (0.9% to 25.1%), and 65.9% (49.4% to 79.9%), respectively. Median (95% CI) DOR was 16.9 (5.6 to not estimable (NE)), 13.9 (8.2 to NE), 14.0 (2.9 to NE), 15.9 (12.6 to NE), and 4.1 (3.4 to 5.6) months, respectively. Median (95% CI) progression-free survival was 8.2 (6.0 to 18.1), 11.3 (8.0 to 20.7), 5.5 (4.2 to 8.2), 2.9 (1.4 to 5.3), and 4.9 (4.2 to 5.5) months, respectively. Treatment-related treatment-emergent adverse events (TR-TEAEs) were experienced by 39 (95.1%), 41 (95.3%), 38 (84.4%), 19 (73.1), and 39 (90.7%) patients, respectively, with 24 (58.5%), 26 (60.5%), 9 (20.0%), 6 (23.1%), and 23 (53.5%) experiencing Grade 3-4 TR-TEAEs.
CONCLUSIONS: Ociperlimab and tislelizumab±chemotherapy demonstrated a manageable safety profile and preliminary antitumor activity in patients with NSCLC or ES-SCLC. Findings from this small phase I study should be interpreted with caution.
METHODS: AdvanTIG-105 was a phase I/Ib, open-label, multicenter clinical trial of ociperlimab plus tislelizumab with or without chemotherapy in patients with unresectable locally advanced or metastatic solid tumors, including NSCLC and ES-SCLC (NCT04047862). The dose-expansion cohorts received ociperlimab (anti-T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domain) 900 mg intravenously and tislelizumab (anti-programmed cell death-protein 1) 200 mg intravenously every 3 weeks (Q3W) ± chemotherapy for four cycles, followed by ociperlimab 900 mg intravenously and tislelizumab 200 mg intravenously Q3W. The primary endpoint was the objective response rate. Other key endpoints included duration of response and safety.
RESULTS: As of August 7, 2024, patients with untreated squamous NSCLC (sqNSCLC; n=41), untreated non-sqNSCLC (n=43), untreated programmed cell death-ligand 1+ NSCLC (tumor cell ≥1%; n=45), checkpoint inhibitor-experienced NSCLC (n=26), and untreated ES-SCLC (n=43) were treated in the dose-expansion phase; of these, 40, 42, 45, 26, and 41 patients, respectively, were efficacy evaluable. ORR (95% CI) was 55.0% (38.5% to 70.7%), 54.8% (38.7% to 70.2%), 40.0% (25.7% to 55.7%), 7.7% (0.9% to 25.1%), and 65.9% (49.4% to 79.9%), respectively. Median (95% CI) DOR was 16.9 (5.6 to not estimable (NE)), 13.9 (8.2 to NE), 14.0 (2.9 to NE), 15.9 (12.6 to NE), and 4.1 (3.4 to 5.6) months, respectively. Median (95% CI) progression-free survival was 8.2 (6.0 to 18.1), 11.3 (8.0 to 20.7), 5.5 (4.2 to 8.2), 2.9 (1.4 to 5.3), and 4.9 (4.2 to 5.5) months, respectively. Treatment-related treatment-emergent adverse events (TR-TEAEs) were experienced by 39 (95.1%), 41 (95.3%), 38 (84.4%), 19 (73.1), and 39 (90.7%) patients, respectively, with 24 (58.5%), 26 (60.5%), 9 (20.0%), 6 (23.1%), and 23 (53.5%) experiencing Grade 3-4 TR-TEAEs.
CONCLUSIONS: Ociperlimab and tislelizumab±chemotherapy demonstrated a manageable safety profile and preliminary antitumor activity in patients with NSCLC or ES-SCLC. Findings from this small phase I study should be interpreted with caution.